{"analyses":[{"ciLowerLimit":"0.568","ciNumSides":"TWO_SIDED","ciPctValue":"97.5","ciUpperLimit":"0.993","estimateComment":"Stratified HR, i.e., based on analysis stratified by randomization stratification factors.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0105","paramType":"Hazard Ratio (HR)","paramValue":"0.751","statisticalMethod":"1-sided stratified log-rank p-value"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.0","upperLimit":"9.2","value":"7.7"},{"groupId":"OG001","lowerLimit":"4.7","upperLimit":"8.3","value":"6.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"162"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to date of death due to any cause. Participants last known to be alive were censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with inotuzumab ozogamicin at a starting dose of 1.8 mg/m\\^2 (according to body surface area) per cycle with a divided-dose regimen using 3 weekly administrations. Participants received 0.8 mg/m\\^2/cycle on Week 1 (Day 1), followed by 0.5 mg/m\\^2 on Week 2 (Day 8) and Week 3 (Day 15) of a 21-day cycle, and administered as an intravenous infusion over 60 minutes. For participants who achieved a CR or CRi, or to allow recovery from toxicity, the length of Cycle 1 could be extended up to 28 days (ie, 1 week treatment-free interval starting on Day 21). For participants who achieved CR or CRi, the inotuzumab ozogamicin dose administered on Week 1 was reduced to 0.5 mg/m\\^2 (for a total cycle dose of 1.5 mg/m\\^2/cycle) for Cycles 2 through 6 (maximum number of cycles permitted). For Cycles 2 through 6, the cycle length was 28 days for all participants (regardless of remission status).","id":"OG000","title":"Inotuzumab Ozogamicin"},{"description":"Participants received fludarabine, cytarabine, granulocyte-colony stimulating factor (FLAG), mitoxantrone + cytarabine (MXN/Ara-C), or high-dose cytarabine (HIDAC), according to the Investigator's choice.","id":"OG001","title":"Defined Investigator's Choice of Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"ITT population - included all participants randomized. Although only 143 participants were treated in the Defined Investigator's Choice of Chemotherapy arm, all 162 randomized participants were included in the ITT population.","reportingStatus":"POSTED","timeFrame":"Up to 5 years after randomization or 2 years from randomization of the last participant, whichever occurs first.","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}